Westfield Capital Management Co. LP Acquires 663,817 Shares of Vaxcyte, Inc. $PCVX

Westfield Capital Management Co. LP increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,732,715 shares of the company’s stock after purchasing an additional 663,817 shares during the period. Westfield Capital Management Co. LP’s holdings in Vaxcyte were worth $134,452,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of PCVX. CWM LLC raised its holdings in Vaxcyte by 197.3% during the 2nd quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after buying an additional 1,115 shares during the period. Virtus Investment Advisers LLC raised its holdings in shares of Vaxcyte by 45.8% during the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after acquiring an additional 857 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Vaxcyte by 96.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock worth $117,000 after acquiring an additional 1,596 shares during the period. Osaic Holdings Inc. lifted its position in Vaxcyte by 110.8% in the 2nd quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock valued at $128,000 after acquiring an additional 2,028 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in Vaxcyte by 401.6% in the 2nd quarter. AlphaQuest LLC now owns 4,429 shares of the company’s stock worth $144,000 after purchasing an additional 3,546 shares during the period. 96.78% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the sale, the senior vice president owned 14,534 shares in the company, valued at $696,469.28. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the transaction, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. BTIG Research lifted their price target on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a research note on Monday, February 2nd. Finally, Needham & Company LLC lifted their price objective on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and an average price target of $94.50.

Vaxcyte Stock Up 2.6%

NASDAQ:PCVX opened at $62.97 on Thursday. The firm has a market capitalization of $8.24 billion, a price-to-earnings ratio of -11.21 and a beta of 1.33. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $83.33. The stock’s 50 day moving average price is $51.12 and its two-hundred day moving average price is $43.58.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter in the prior year, the business earned ($1.12) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.